In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: October 2009

Executive Summary

Sanofi-Aventis was the standout in pharma alliances, penning three of the big deals, which together were worth over $1 billion in potential deal value. Onyx's buy of cancer and immunology biotech Proteolix topped the M&A chart at $851 million. In devices, notable was Kimberly-Clark, which followed up last month's Baylis acquisition with another in pain management--I-Flow, for $309 million, over twice that company's sales. Almost 40% of pharma financing came from Talecris' $600 million notes offering. And fundraising for the device industry was boosted by an $88 million IPO completed by AGA Medical Holdings, and a $55 million Series B from TransEnterix.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV003230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel